In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Genetic factors of hereditary affliction to ischemic heart disease and atherosclerosis of the left main coronary artery

Session Poster Session 1

Speaker Evgeny Ivantsov

Congress : Acute Cardiovascular Care 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes - Pathophysiology and Mechanisms
  • Session type : Poster Session
  • FP Number : P164

Authors : EN Ivantsov (Kazan,RU), FA Magamedkerimova (Kazan,RU), NR Khasanov (Kazan,RU), DA Zateyshcikov (Kazan,RU)

Authors:
EN Ivantsov1 , FA Magamedkerimova1 , NR Khasanov1 , DA Zateyshcikov1 , 1Kazan State Medical University - Kazan - Russian Federation ,

Citation:

Introduction. Ischemic heart disease (IHD) is the leading cause of death among adult populations in developed countries. Factors that influence the risk of IHD development are divided into non-modifiable (including genetic factors andfamily history of Coronary Artery Disease) and modifiable. Smoking is the most significant of the modifiable risk factors. Materials and Methods. To exclude the influence of the most significant modifiable cardiovascular risk factor, smokers were not included in the study. A total of 122 non-smokers with Acute Coronary Syndrome (ACS), hospitalized in 2016-2017 years in the department of emergency cardiology of the city hospital, aged 29 to 87 (mean age 66.5±1.01), were included in the study, was composed of 50 males and 72 females. The group studied contained 32 patients with Unstable Angina and 90 patients with Myocardial Infarction of different localizations, including 61 patients with ST elevation on ECG. In all patients a family history of CAD assessment, coronary angiography and identification of the single nucleotide polymorphism rs699947 of gene VEGF-A were conducted. The results are reported in the form of M±m, with categorical data assessment done using Fisher’s exact test, and the odds ratio estimated. Results and discussion. Family history of CAD was observed less frequently among carriers of genotype CC (13.5%) compared to AA (51.7%, ?(Fisher)=0.001, OR=0.146, 95% CI=0.044-0.480) and AC (42.9%, ?(Fisher)=0.003, OR=0.208, 95% CI=0.071-0.614), as well as in all A allele carriers (45.9%, ?=0.0004, OR=0.184, 95% CI=0.065-0.519). In A allele carriers, family history of CAD was observed more frequently than in C allele carriers (31.2%, ?(Fisher)=0,03; OR=1.871, 95% CI=1.015-3.450). Moderate and severe Left Main Coronary Artery (LMCA) stenosis appeared in 17 (13.9%) patients. The highest frequency of stenosis was observed in AC genotype carriers (23.2%) compared to other patients (4.3%, ?(Fisher)=0.0036, OR=4.686, 95% CI=1.431-15.346). The analysis showed that LMCA stenosis appeared less frequently in CC genotype carriers (2,7%) compared to AC (23.2%, ?(Fisher)=0.007, OR=0.092, 95% CI=0.011-0.737) and A allele carriers (18.8%, ?(Fisher)=0.035, OR=0.120, 95% CI=0.015-0.940).
Discussion and conclusions.The findings indicate that allele A rs699947 of VEGF-A gene is associated with hereditary affliction to IHD and the AC genotype is associated with atherosclerosis of LMCA with the identified protective function of CC genotype related to the hereditary affliction to IHD and significant atherosclerosis of LMCA. Carriers of genotype CC rs699947 of gene VEGF-A have a reduced risk of atherosclerosis of LMCA, whereas ACS patients who are carriers of allele A, especially genotype AC, have an increased probability of LMCA stenosis.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are